The data — six presentations — originally were to be presented at the 2020 annual conference of the American Academy of Neurology (AAN), which was canceled due to the COVID-19 pandemic. Instead, the data were posted online.
“The data shared at AAN represent our ongoing efforts to improve the MS treatment experience and deliver therapies that provide clinically meaningful benefits to individuals living with this chronic disease,” Bernd Kieseier, MD, said in a press release. Kieseier is executive director, head of Global MS, Worldwide Medical, Biogen.
In one presentation, “Improved Gastrointestinal Tolerability Profile with Diroximel Fumarate Compared to Dimethyl Fumarate in Relapsing MS Patients,” researchers analyzed data from the clinical trial EVOLVE-MS-2 (NCT03093324).
In EVOLVE-MS-2, participants with relapsing-remitting MS (RRMS) were assigned randomly to treatment with either Tecfidera (240 mg) or Vumerity (462 mg) for five weeks. These two oral medications are different formulations of the same active ingredient — monomethyl fumarate. The main purpose of the trial was to compare the safety and tolerability of the two therapies, especially regarding gastrointestinal side effects.
Among 502 participants who rated their gastrointestinal (GI) symptoms at least once, fewer patients receiving Vumerity, compared to Tecfidera, reported that GI symptoms interfered with daily life “quite a bit” or “extremely.”
The specific symptoms were: nausea (2.4% with Vumerity vs. 6.8% with Tecfidera), vomiting (1.2% vs. 5.6%), upper abdominal pain (1.2% vs. 6.8%), lower abdominal pain (1.2% vs. 3.2%), and diarrhea (3.6% vs. 6.4%).
Also, treatment discontinuation due to GI symptoms was significantly lower with Vumerity (0.8%) than with Tecfidera (4.8%).
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?